Wire · opportunities
FDA Approves Zanidatamab Combination Regimens for HER2 Gastric GEJ or Esophageal Cancer
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 August 2026 · Fusion42 review
The FDA approved zanidatamab-hrii (Ziihera) in combination regimens as first-line treatment for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, along with companion diagnostic devices. The approval followed positive results from a global trial showing significant improvements in overall survival and progression-free survival.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 25 Aug 2026 and 8 Sep 2026.
◆ ◆ The Wire takeaway
The FDA approval opens a valuable US commercial market for companies making complementary HER2 diagnostics and therapies. You should engage now with oncology practices to establish zanidatamab as a preferred treatment option ahead of wider adoption.
◆ Coverage
10 sources · first reported 25 Aug 2026 · latest 8 Sep 2026
◆ Related on Wire
◆ Topics